Search

Displaying results 771 - 780 of 6198 in total
  1. Drug

    Secukinumab

    go.drugbank.com/drugs/DB09029
    ApprovedInvestigational

    [A249840] Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). … [L39600] By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders.

  2. Drug

    Flurpiridaz F-18

    go.drugbank.com/drugs/DB18773
    Approved

    coronary artery disease (CAD). … [A264519] Flurpiridaz F-18 is an analog of pyridaben, a mitochondrial complex 1 (MC-1) inhibitor.[L51659]

  3. Drug

    Sodium tartrate

    go.drugbank.com/drugs/DB13707
    ApprovedWithdrawn

    Sodium tartrate is a disodium salt of l-( + )-tartaric acid that is identified by transparent, colorless, and odorless crystals. It is obtained as a byproduct of wine manufacturing. … It acts as an emulsifier and pH control agent in food products [L2590].

  4. Drug

    Sarecycline

    go.drugbank.com/drugs/DB12035
    ApprovedInvestigational

    Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 … The acne often presents physically as a mixture of non-inflammatory and inflammatory lesions mainly on the face but on the back and chest as well [L4814].

  5. Drug

    Iodide I-123

    go.drugbank.com/drugs/DB09420
    ApprovedInvestigational

    Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. … After incorporation, a gamma camera is used to detect the decay by electron capture to tellurium-123.

  6. Drug

    Catumaxomab

    go.drugbank.com/drugs/DB06607
    ApprovedWithdrawn

    Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites [L1122].

  7. Drug

    Olutasidenib

    go.drugbank.com/drugs/DB16267
    ApprovedInvestigational

    [L44256,L44261] It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with a susceptible IDH1 mutation as determined by an FDA-approved test. … Olutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022.

  8. Drug

    Phendimetrazine

    go.drugbank.com/drugs/DB01579
    ApprovedIllicit

    Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances and in the US since 1970.

  9. Drug

    Cyanocobalamin Co-60

    go.drugbank.com/drugs/DB09387
    ApprovedWithdrawn

    Cyanocobalamin Co-60 was used for the diagnosis of pernicious anemia, but now it is withdrawn from the market in the US for unknown reasons. … Cyanocobalamin Co-60 is an analog of Vitamin B12 labeled with Co60.

  10. Drug

    Sotagliflozin

    go.drugbank.com/drugs/DB12713
    ApprovedInvestigational

    [L39734] A similar approval has also been sought in the US, but the FDA has since published a proposal to refuse the approval because the data submitted did not show that it was safe under the proposed … [L39705] Its potency in inhibiting SGLT2 is similar to that of other SGLT2 inhibitors, such as [canagliflozin] and [dapagliflozin], but its potency in inhibiting SGLT1 is >10-fold higher than its predecessors